© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Pfizer/BioNTech Combination Flu/COVID-19 Shot Misses Key Primary Phase 3 Endpoint
August 16, 2024
The influenza/COVID-19 combination did not prove noninferior to the comparator flu vaccine against influenza B, the companies reported.
A Primer on neffy for Primary Care: Q&A with Leading US Allergist Thomas Casale, MD
August 16, 2024
Patients were the driving force behind the development of the needle-free epinephrine nasal spray, Casale says; he answers more questions with primary care in mind.
FDA Accepts Vertex NDA for Suzetrigine, Investigational Oral Nonopioid Analgesic for Acute pain
August 15, 2024
If approved the selective NaV1.8 pain signal inhibitor would reflect the first new class of pain management medication in more than 20 years.
Neffy, First Needle-Free Epinephrine, Fills a Deep Need for Patients, says Allergy Expert
August 15, 2024
The approval of neffy (epinephrine nasal spray) could help individuals and caregivers act sooner and feel safer treating a type 1 allergic reaction.
White Coat & Masked Hypertension: A Primary Care Guideline Topline
August 15, 2024
White coat and masked hypertension can be elusive and dangerous. Click through a topline look at recommendations from the 2017 ACC/AHA hypertension guidelines.
A Primer on Congenital Adrenal Hyperplasia with Expert Steroid Biologist Richard Auchus, MD, PhD
August 14, 2024
Richard J Auchus, MD, PhD, a preeminent steroid biologist, provides a concise and thorough primer on CAH and the challenges in managing the disorder safely and effectively.
Routine Laboratory Study Results Not Clinically Useful for Diagnosing Long COVID: New Analysis
August 14, 2024
Of the 25 routine lab tests studied, none proved clinically useful for diagnosing COVID-19, even among participants with a high long COVID symptom burden.
SGLT-2 Inhibitor Prescribing in the US is Failing People who Need them Most
August 13, 2024
No health system across the 28 analyzed in this study demonstrated appropriate SGLT2i prescribing for more than 25% of eligible individuals.
5 Obesity Drugs Worth Watching: 2024-2025
August 13, 2024
Incretin analogues, an oral glucose formulation that targets endogenous nutrient-sensing pathways and a cannabinoid receptor 1 antagonist are in the new mix.
Tirzepatide Real-World Benefit Found Greater for CV, Renal Outcomes vs GLP-1 RAs in Adults with T2D
August 12, 2024
In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.